Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial

AIM: This study was performed to evaluate the potential efficacy of silymarin in the management of anti-tuberculosis medication’s induced liver injury. BACKGROUND: Hepatic toxicity is the most serious complication in treatment of tuberculosis. METHODS: In a randomized double blind clinical trial (AC...

Descripción completa

Detalles Bibliográficos
Autores principales: Marjani, Majid, Fahim, Fanak, Sadr, Makan, Kazempour Dizaji, Mehdi, Moniri, Afshin, Khabiri, Shadi, Tabarsi, Payam, Velayati, Ali Akbar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Shaheed Beheshti University of Medical Sciences 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536020/
https://www.ncbi.nlm.nih.gov/pubmed/31191838
_version_ 1783421680828284928
author Marjani, Majid
Fahim, Fanak
Sadr, Makan
Kazempour Dizaji, Mehdi
Moniri, Afshin
Khabiri, Shadi
Tabarsi, Payam
Velayati, Ali Akbar
author_facet Marjani, Majid
Fahim, Fanak
Sadr, Makan
Kazempour Dizaji, Mehdi
Moniri, Afshin
Khabiri, Shadi
Tabarsi, Payam
Velayati, Ali Akbar
author_sort Marjani, Majid
collection PubMed
description AIM: This study was performed to evaluate the potential efficacy of silymarin in the management of anti-tuberculosis medication’s induced liver injury. BACKGROUND: Hepatic toxicity is the most serious complication in treatment of tuberculosis. METHODS: In a randomized double blind clinical trial (ACTRN12610000643077), 55 cases with hepatotoxicity caused by anti-tuberculosis drugs were divided into two groups. Informed consents were obtained. The intervention group received silymarin and the control group received placebo. Severity of liver injury, the duration necessary for normalization of liver function and hospital stay were compared between the two groups. RESULTS: There was not any statistically significant difference in the rate of adverse effects between silymarin and placebo groups. CONCLUSION: Although silymarin is considered a safe herbal medication, it was not effective to treat hepatic toxicity of anti-tuberculosis drugs.
format Online
Article
Text
id pubmed-6536020
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Shaheed Beheshti University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-65360202019-06-12 Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial Marjani, Majid Fahim, Fanak Sadr, Makan Kazempour Dizaji, Mehdi Moniri, Afshin Khabiri, Shadi Tabarsi, Payam Velayati, Ali Akbar Gastroenterol Hepatol Bed Bench Original Article AIM: This study was performed to evaluate the potential efficacy of silymarin in the management of anti-tuberculosis medication’s induced liver injury. BACKGROUND: Hepatic toxicity is the most serious complication in treatment of tuberculosis. METHODS: In a randomized double blind clinical trial (ACTRN12610000643077), 55 cases with hepatotoxicity caused by anti-tuberculosis drugs were divided into two groups. Informed consents were obtained. The intervention group received silymarin and the control group received placebo. Severity of liver injury, the duration necessary for normalization of liver function and hospital stay were compared between the two groups. RESULTS: There was not any statistically significant difference in the rate of adverse effects between silymarin and placebo groups. CONCLUSION: Although silymarin is considered a safe herbal medication, it was not effective to treat hepatic toxicity of anti-tuberculosis drugs. Shaheed Beheshti University of Medical Sciences 2019 /pmc/articles/PMC6536020/ /pubmed/31191838 Text en ©2019 RIGLD, Research Institute for Gastroenterology and Liver Diseases This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Marjani, Majid
Fahim, Fanak
Sadr, Makan
Kazempour Dizaji, Mehdi
Moniri, Afshin
Khabiri, Shadi
Tabarsi, Payam
Velayati, Ali Akbar
Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
title Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
title_full Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
title_fullStr Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
title_full_unstemmed Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
title_short Evaluation of Silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
title_sort evaluation of silymarin for management of anti-tuberculosis drug induced liver injury: a randomized clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536020/
https://www.ncbi.nlm.nih.gov/pubmed/31191838
work_keys_str_mv AT marjanimajid evaluationofsilymarinformanagementofantituberculosisdruginducedliverinjuryarandomizedclinicaltrial
AT fahimfanak evaluationofsilymarinformanagementofantituberculosisdruginducedliverinjuryarandomizedclinicaltrial
AT sadrmakan evaluationofsilymarinformanagementofantituberculosisdruginducedliverinjuryarandomizedclinicaltrial
AT kazempourdizajimehdi evaluationofsilymarinformanagementofantituberculosisdruginducedliverinjuryarandomizedclinicaltrial
AT moniriafshin evaluationofsilymarinformanagementofantituberculosisdruginducedliverinjuryarandomizedclinicaltrial
AT khabirishadi evaluationofsilymarinformanagementofantituberculosisdruginducedliverinjuryarandomizedclinicaltrial
AT tabarsipayam evaluationofsilymarinformanagementofantituberculosisdruginducedliverinjuryarandomizedclinicaltrial
AT velayatialiakbar evaluationofsilymarinformanagementofantituberculosisdruginducedliverinjuryarandomizedclinicaltrial

Ejemplares similares